Review
Neurosciences
Michele Fabrazzo, Mariangela Boccardi, Salvatore Cipolla, Raffaele Galiero, Claudia Tucci, Francesco Perris, Ester Livia Di Caprio, Francesco Catapano, Ferdinando Carlo Sasso
Summary: Neuropsychiatric disorders have been linked to bullous pemphigoid (BP), with antipsychotics identified as potential inducing factors. However, the exact biological mechanisms and timeline between neuropsychiatric disorders and BP remain undefined. Clinicians should consider BP as a possible adverse effect of psychotropic medications when treating psychiatric patients.
Article
Clinical Neurology
Ching-Hua Lin, Hung-Yu Chan, Chun-Chi Hsu, Feng-Chua Chen
Summary: The study showed that discharged patients with bipolar mania had a significantly lower rehospitalization risk when using long-acting injectable antipsychotics (LAIs) compared to oral antipsychotics. The prescription rate of LAIs increased significantly during the study period, especially for second-generation antipsychotics (SGA-LAIs).
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Pharmacology & Pharmacy
Joerg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer, Claus Wolff-Menzler
Summary: Real-world evidence from Germany shows that long-acting injectable antipsychotics are associated with improved medication adherence and reduced risk of treatment discontinuation compared to oral antipsychotics in patients with schizophrenia.
CLINICAL DRUG INVESTIGATION
(2021)
Article
Psychology, Clinical
Su-Chen Fang, Cheng-Yi Huang, Yu-Hsuan Joni Shao
Summary: This study found that the early use of long-acting injectable antipsychotics in schizophrenia can reduce the risk of mortality and relapse, as well as improve long-term treatment adherence.
JOURNAL OF CLINICAL PSYCHIATRY
(2022)
Article
Pharmacology & Pharmacy
Yifei Liu, Mark E. Patterson, Suman Sahil, Steven C. Stoner
Summary: This study investigated the prescribing patterns of long-acting injectable antipsychotics and their oral/short-acting injectable equivalents for inpatients. The results showed that these medications were underutilized from 2010 to 2016, and there were significant changes in the prescribing patterns of paliperidone palmitate and risperidone among second-generation antipsychotic LAIs.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Clinical Neurology
Lingyue Ma, Qian Xiang, Nan Zhao, Changqing Hu, Meng Fang, Yunlong Tan, Song Chen, Zining Wang, Pinglan Liu, Kaoxiang Sun, Youxin Li, Fuxi Wu, Hongjun Tian, Maosheng Fang, Xia Zhao, Gang Wang, Yimin Cui
Summary: The study revealed that genetic polymorphisms of the CYP2D6 gene can affect the pharmacokinetics of risperidone, while genetic polymorphisms of the ABCB1 gene can influence the clearance rate of risperidone active moiety.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Pharmacology & Pharmacy
Andrea Aguglia, Laura Fusar-Poli, Antimo Natale, Andrea Amerio, Irene Espa, Veronica Villa, Giovanni Martinotti, Giuseppe Carra, Francesco Bartoli, Armando D'Agostino, Gianluca Serafini, Mario Amore, Eugenio Aguglia, Giovanni Ostuzzi, Corrado Barbui
Summary: This study examined factors associated with medication adherence to long-acting injectable antipsychotics (LAI) in individuals with severe psychiatric disorders. The results showed that younger age, living with others, lower psychiatric symptom scores, fewer adverse events, and positive attitude towards medication were associated with higher medication adherence. The study highlights the importance of attitude towards medication and suspicious/hostile traits in predicting adherence to LAI.
PHARMACOPSYCHIATRY
(2022)
Article
Clinical Neurology
John Lauriello, Peter J. Weiden, Carole D. Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman, Amy K. O'Sullivan
Summary: The use of long-acting injectable antipsychotic aripiprazole lauroxil (AL) has shown significant reductions in inpatient costs and an increase in outpatient pharmacy costs for treating schizophrenia in adults. Patients initiating AL experienced decreased mental health-related inpatient admissions and emergency room visits, indicating potential for greater clinical stability compared to previous treatments.
Article
Clinical Neurology
Francesco Bartoli, Bianca Bachi, Angela Calabrese, Riccardo Matteo Cioni, Pierluca Guzzi, Christian Nasti, Dario Palpella, Filippo Fabio Barbieri, Serena Limonta, Cristina Crocamo, Giuseppe Carra
Summary: This mirror-image study explored the effect of initiating long-acting injectable antipsychotics (LAIs) on the number of emergency department visits and days of hospitalization in individuals with bipolar disorder (BD). The results showed that initiating LAIs overall reduced both emergency department visits and hospitalization days in BD patients. However, this effect was only observed in participants who continued using LAIs for the entire 12-month observation period and were treated with a second-generation antipsychotic LAI. The reduction in hospitalization days was more significant during manic episodes and for compulsory admissions.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Medicine, General & Internal
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Marco Giuseppe Alberto Nobili, Rodolfo Sgro, Paola Rocca
Summary: Studies have shown that long-acting injectable second-generation antipsychotics (SGA-LAIs) can improve subjective quality of life, well-being, and satisfaction in schizophrenia patients. SGA-LAIs have been reported to be superior to oral equivalents and haloperidol-LAI. However, the evidence is limited due to a lack of studies and methodological issues.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Lana Ganoci, Vladimir Trkulja, Maja Zivkovic, Tamara Bozina, Marina Sagud, Mila Lovric, Nada Bozina
Summary: The study investigated the relationship between ABC gene polymorphisms and CYP genotypes in the context of long-acting risperidone treatment. It found that the impact of CYP2D6 genotype on risperidone exposure was dependent on the ABCG2 421C > A polymorphism, while ABC gene polymorphisms affected clinical response independently of systemic risperidone disposition.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Biochemistry & Molecular Biology
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici, Enrico Capuzzi
Summary: Treatment discontinuation is a challenge in clinical settings. Long acting injectable (LAI) antipsychotics are underutilized despite their potential benefits. This study aimed to identify the factors associated with LAI discontinuation in a real-world setting.
Article
Medicine, General & Internal
Cheng-Yi Huang, Su-Chen Fang, Yu-Hsuan Joni Shao
Summary: The study found that the use of long-acting injectable antipsychotics in patients with newly diagnosed schizophrenia is associated with decreased overall mortality and suicide risk. Early treatment with LAIs within the first 2 years of oral antipsychotic initiation was also linked to reduced suicide mortality risk. This suggests that the use of LAIs early in treatment should be actively considered for patients with newly diagnosed schizophrenia.
Article
Public, Environmental & Occupational Health
Michelle R. Lofwall, Laura C. Fanucchi
Summary: The opioid epidemic is worsening, with treatment access issues, especially in rural areas. The development of new LAB injectables holds promise to improve treatment access and retention.
PREVENTIVE MEDICINE
(2021)
Article
Medicine, General & Internal
Sandra I. Ralat, Giselle Alicea-Cuprill, Yashira Arroyo, William Otero
Summary: This study tested a psychosocial intervention to improve medication adherence and health behaviors in BD patients. The intervention was found to have medium to large effects on medication adherence, attitudes towards medication, and manic symptoms, with high levels of participant satisfaction. Further research with a larger sample size is needed.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Clinical Neurology
Benjamin I. Goldstein, Bernhard T. Baune, David J. Bond, Pao-Huan Chen, Lisa Eyler, Andrea Fagiolini, Fabiano Gomes, Tomas Hajek, Jessica Hatch, Susan L. McElroy, Roger S. McIntyre, Miguel Prieto, Louisa G. Sylvia, Shang-Ying Tsai, Andrew Kcomt, Jess G. Fiedorowicz
Review
Psychiatry
Alessandro Cuomo, Bruno Beccarini Crescenzi, Simone Bolognesi, Arianna Goracci, Despoina Koukouna, Rodolfo Rossi, Andrea Fagiolini
ANNALS OF GENERAL PSYCHIATRY
(2020)
Review
Psychiatry
Andrea Fagiolini, Jose Angel Alcala, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Scholin, Ingo Bernd Vernaleken
ANNALS OF GENERAL PSYCHIATRY
(2020)
Article
Clinical Neurology
Michael Cronquist Christensen, Roger S. McIntyre, Ioana Florea, Henrik Loft, Andrea Fagiolini
Summary: This study analyzed the efficacy and tolerability of vortioxetine in patients with major depressive disorder. The results showed that vortioxetine 20 mg/day was more effective than 10 mg/day, with similar tolerability. In flexible-dose studies, nearly half of the patients received 20 mg/day after 1 week and two-thirds received 20 mg/day as their final dosage.
Article
Psychiatry
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Summary: This study investigates the experience of emotional blunting in depression, its impact on overall functioning and quality of life, and the perspectives of patients and healthcare providers. The findings show that almost three-quarters of patients in the acute phase of depression and one-quarter of those in remission reported severe emotional blunting. Furthermore, approximately 56% of patients believed that their emotional blunting was caused by their depression, while 45% believed that their antidepressant medication was negatively affecting their emotions. Over one-third of patients were considering stopping or had stopped their antidepressant as a result.
ANNALS OF GENERAL PSYCHIATRY
(2022)
Article
Psychiatry
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Summary: This study investigated the experience and impact of emotional blunting in patients with depression from the perspectives of both patients and healthcare providers. The results indicate that healthcare providers may underestimate the prevalence of emotional blunting in depression patients and the severity of its impact on patient functioning.
ANNALS OF GENERAL PSYCHIATRY
(2022)
Article
Psychiatry
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Summary: This international online survey found that a high proportion of patients with depression self-reported exposure to childhood and/or recent traumatic events, and emotional blunting was more severe in patients who reported having experienced severe trauma. However, history of psychological trauma in patients with MDD appeared to be under-recognized by HCPs. Improved recognition of patients who have experienced psychological trauma and are experiencing emotional blunting may permit more targeted therapeutic interventions, potentially resulting in improved treatment outcomes.
ANNALS OF GENERAL PSYCHIATRY
(2022)
Article
Psychiatry
Michael Cronquist Christensen, Hongye Ren, Andrea Fagiolini
Summary: Emotional blunting is a common symptom in people with depression and has a substantial negative impact on their daily functioning, well-being, and quality of life. This study investigated the experience of emotional blunting in acute and remission phases of depression and found that it significantly impaired overall functioning and health-related quality of life from the patient perspective.
ANNALS OF GENERAL PSYCHIATRY
(2022)
Article
Clinical Neurology
Michael Adair, Michael Cronquist Christensen, Ioana Florea, Henrik Loft, Andrea Fagiolini
Summary: This study assessed the efficacy and tolerability of Vortioxetine in treating anxiety symptoms in patients with major depressive disorder. The results showed a clear dose-response relationship for Vortioxetine in improving depressive, anxiety, and functioning symptoms. Additionally, Vortioxetine was found to be superior to agomelatine in patients with an inadequate response to prior therapy.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Michael C. Christensen, Roger S. McIntyre, Michael Adair, Ioana Florea, Henrik Loft, Andrea Fagiolini
Summary: This study analyzed the clinical relevance of using vortioxetine 20 mg/day vs 10 mg/day in patients with major depressive disorder (MDD), and found that vortioxetine 20 mg/day provided a more rapid and greater improvement in depressive symptoms.
Editorial Material
Clinical Neurology
Andrea Fagiolini, Alessandro Cuomo
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Flavia Privitera, Maria A. Trusso, Floriana Valentino, Gabriella Doddato, Chiara Fallerini, Giulia Brunelli, Romina D'Aurizio, Simone Furini, Arianna Goracci, Andrea Fagiolini, Francesca Mari, Alessandra Renieri, Francesca Ariani
Summary: This study focuses on a large family with 12 members affected by bipolar disorder. Through whole-exome sequencing, certain genes, including CLN6 and ZNF92, were identified as having variations associated with the disorder. The findings suggest that heterozygous carriers of CLN6 may develop bipolar disorder later in life if combined with additional variants in ZNF92.
BRAZILIAN JOURNAL OF PSYCHIATRY
(2023)
Article
Clinical Neurology
Alessandro Cuomo, Giovanni Barilla, Matteo Cattolico, Pietro Carmellini, Alessandro Spiti, Andrea Pozza, Andrea Fagiolini
Summary: This retrospective study supports the use of intravenous valproic acid (IV-VPA) as a more efficacious treatment option for patients with Bipolar Disorder, particularly in acute settings where rapid symptom improvement is crucial. Both oral and IV-VPA were found to be safe and well-tolerated.
Article
Psychiatry
Ludovico Mineo, Alessandro Rodolico, Giorgio Alfredo Spedicato, Andrea Aguglia, Simone Bolognesi, Carmen Concerto, Alessandro Cuomo, Arianna Goracci, Giuseppe Maina, Andrea Fagiolini, Mario Amore, Eugenio Aguglia
Summary: This study employed a cross-diagnostic cluster analysis to identify distinct subgroups among depressed patients. The results revealed three clusters: Mild, Moderate, and Mixed, which were associated with different levels of clinical severity and outcomes.
EUROPEAN PSYCHIATRY
(2022)
Review
Clinical Neurology
Christoph U. Correll, Koen Demyttenaere, Andrea Fagiolini, Goran Hajak, Stefano Pallanti, Giorgio Racagni, Swaran Singh
